S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
Free Trial
NASDAQ:RTRX

Travere Therapeutics (RTRX) Stock Price, News & Analysis

→ Now Open: Crypto emergency update (From InvestorPlace) (Ad)
Free RTRX Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$5.78
▼
$6.02
50-Day Range
$24.25
▼
$28.18
52-Week Range
$8.98
▼
$24.96
Volume
972,749 shs
Average Volume
412,277 shs
Market Capitalization
$296.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisCompetitorsHeadlinesSocial Media
RTRX stock logo

About Travere Therapeutics Stock (NASDAQ:RTRX)

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.

RTRX Stock News Headlines

April 17, 2024 | markets.businessinsider.com
Critical Insights From Travere Therapeutics Analyst Ratings: What You Need To Know
February 23, 2024 | realmoney.thestreet.com
Travere Therapeutics price target lowered by $3 at H.C. Wainwright, here's why
April 19, 2024 | InvestorPlace (Ad)
You’re invited: Biggest crypto event of 2024
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
February 23, 2024 | msn.com
Travere Therapeutics gains as EU backs kidney disease therapy
February 21, 2024 | msn.com
New Debt & Financing Risk for Travere Therapeutics, Inc. – What’s the Latest?
February 17, 2024 | realmoney.thestreet.com
Travere Therapeutics price target raised by $4 at Citi, here's why
February 16, 2024 | markets.businessinsider.com
Travere Therapeutics: Hold Rating Amidst Filspari’s Steady Performance and Emerging Market Competition
February 14, 2024 | benzinga.com
Earnings Preview For Travere Therapeutics
April 19, 2024 | InvestorPlace (Ad)
You’re invited: Biggest crypto event of 2024
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
January 11, 2024 | markets.businessinsider.com
Travere Therapeutics: A Strong Buy on Filspari’s Outperformance and Promising Market Prospects
December 7, 2023 | markets.businessinsider.com
Optimistic Outlook for Travere Therapeutics Amid FDA Developments and Strategic Reorganization
December 6, 2023 | msn.com
Travere (TVTX) Up on Latest Portfolio Updates & Reorganization
December 5, 2023 | markets.businessinsider.com
Buy Rating for Travere Therapeutics: Optimism Fueled by Regulatory Prospects and Strategic Reorganization
December 5, 2023 | realmoney.thestreet.com
Travere Therapeutics upgraded to Buy from Neutral at Citi
December 4, 2023 | marketwatch.com
Travere Shares Rise 8.4%; Co. To Cut Staff, Focus on IgAN, HCU Treatments
November 21, 2023 | benzinga.com
Travere Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference
November 8, 2023 | markets.businessinsider.com
Promising Sales Performance and Growth Prospects Solidify Buy Rating for Travere Therapeutics
November 6, 2023 | benzinga.com
Preview: Travere Therapeutics's Earnings
October 31, 2023 | morningstar.com
Travere Therapeutics Inc Ordinary Shares TVTX
September 30, 2023 | msn.com
Wedbush Reiterates Travere Therapeutics (TVTX) Outperform Recommendation
September 22, 2023 | msn.com
Why Former Highflier Travere Therapeutics Just Crashed 41% To A Decade-Low
September 21, 2023 | msn.com
Why Shares of Travere Therapeutics Are Slumping Thursday
September 21, 2023 | markets.businessinsider.com
Back To Back Trial Failures: Analyst Weighs In On Travere Therapeutics' Prospects, Challenges
August 31, 2023 | markets.businessinsider.com
Bank of America Securities Remains a Buy on Travere Therapeutics (TVTX)
July 19, 2023 | marketwatch.com
Mirum Pharmaceuticals to Buy Bile Acid Product Portfolio from Travere Therapeutics
June 26, 2023 | benzinga.com
TVTX ALERT: The Law Offices of Vincent Wong Investigate Travere Therapeutics, Inc. for Potential Violations of Securities Laws
May 3, 2023 | msn.com
Evercore ISI Group Maintains Travere Therapeutics (TVTX) Outperform Recommendation
See More Headlines
Receive RTRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Travere Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/05/2020
Today
4/18/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:RTRX
CUSIP
N/A
CIK
1438533
Web
www.retrophin.com
Phone
(888) 969-7879
Fax
N/A
Employees
221
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($3.46)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-146,430,000.00
Net Margins
-49.13%
Pretax Margin
N/A
Return on Equity
-36.38%
Return on Assets
-14.90%

Debt

Debt-to-Equity Ratio
0.66
Current Ratio
7.23
Quick Ratio
7.14

Sales & Book Value

Annual Sales
$175.34 million
Price / Sales
1.74
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$5.15 per share
Price / Book
1.16

Miscellaneous

Outstanding Shares
51,052,000
Free Float
N/A
Market Cap
$305.80 million
Optionable
Not Optionable
Beta
0.67
The 10 Best AI Stocks to Own in 2024 Cover
The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Eric Dube
    President, Chief Executive Officer & Director
  • Laura M. Clague
    Chief Financial & Accounting Officer
  • Bill Rote
    Senior VP, Head-Research & Development
  • Noah L. Rosenberg
    Chief Medical Officer
  • Elizabeth E. Reed
    Secretary, Senior Vice President & General Counsel

Key Competitors

View All Competitors

RTRX Stock Analysis - Frequently Asked Questions

How were Travere Therapeutics' earnings last quarter?

Travere Therapeutics, Inc. (NASDAQ:RTRX) announced its quarterly earnings results on Thursday, November, 5th. The biopharmaceutical company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($0.59) by $0.15. Travere Therapeutics had a negative trailing twelve-month return on equity of 36.38% and a negative net margin of 49.13%.

What other stocks do shareholders of Travere Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Travere Therapeutics investors own include CVS Health (CVS), Gilead Sciences (GILD), TG Therapeutics (TGTX), Dynavax Technologies (DVAX), Novavax (NVAX), Sangamo Therapeutics (SGMO), Heron Therapeutics (HRTX), Intercept Pharmaceuticals (ICPT), OPKO Health (OPK) and Exelixis (EXEL).

This page (NASDAQ:RTRX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
The “Perfect Storm” for Gold
Gold Safe Exchange
Biden’s $374B Giveaway Into This Sector
DTI
Biden replacement revealed?
Paradigm Press
He Is Giving Away Bitcoin
Crypto Swap Profits
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research
Your Money is Not Safe
American Alternative
The #1 Crypto for 2024
InvestorPlace
Top 5 AI Stocks to Buy for 2024
Market Moving Trends